tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
Company profile
Ticker
TCON
Exchange
Website
CEO
Charles P. Theuer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Tracon Pharmaceuticals Inc
SEC CIK
TCON stock data
Latest filings (excl ownership)
S-1
IPO registration
12 Apr 24
8-K
Results of Operations and Financial Condition
12 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
8-K
Other Events
10 Apr 24
8-K
TRACON Pharmaceuticals Announces Reverse Stock Split
8 Apr 24
8-K
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024
3 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
5 Mar 24
8-K
Other Events
19 Dec 23
Transcripts
TCON
Earnings call transcript
2023 Q4
5 Mar 24
TCON
Earnings call transcript
2023 Q3
9 Nov 23
TCON
Earnings call transcript
2023 Q2
14 Aug 23
TCON
Earnings call transcript
2023 Q1
10 May 23
TCON
Earnings call transcript
2022 Q4
8 Mar 23
TCON
Earnings call transcript
2022 Q3
15 Nov 22
TCON
Earnings call transcript
2022 Q2
11 Aug 22
TCON
Earnings call transcript
2022 Q1
12 May 22
TCON
Earnings call transcript
2021 Q4
16 Mar 22
TCON
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
SC 13G/A
Ikarian Capital, LLC
5 Apr 24
SC 13G/A
aaronson wayne
19 Mar 24
4
Scott B. Brown
13 Mar 24
4
CHARLES THEUER
13 Mar 24
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13D/A
Opaleye Management Inc.
9 Feb 24
4
Change in insider ownership
14 Nov 23
SC 13G
Lincoln Park Capital Fund, LLC
2 Jun 23
4
CHARLES THEUER
28 Apr 23
4
Lisa Johnson-Pratt
21 Apr 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.84 mm | 7.84 mm | 7.84 mm | 7.84 mm | 7.84 mm | 7.84 mm |
Cash burn (monthly) | (no burn) | 781.42 k | 529.33 k | 1.29 mm | (no burn) | 37.92 k |
Cash used (since last report) | n/a | 5.20 mm | 3.53 mm | 8.61 mm | n/a | 252.55 k |
Cash remaining | n/a | 2.63 mm | 4.31 mm | -775.11 k | n/a | 7.58 mm |
Runway (months of cash) | n/a | 3.4 | 8.1 | -0.6 | n/a | 200.0 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Scott B. Brown | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 224,800 | 0.00 | 224,800 |
12 Mar 24 | Theuer Charles | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 518,300 | 0.00 | 518,300 |
10 Nov 23 | Opaleye Management | Common Stock, par value $0.001 per share | Sell | Dispose S | Yes | No | 0.2942 | 440,000 | 129.45 k | 0 |
10 Nov 23 | Opaleye Management | Common Stock, par value $0.001 per share | Sell | Dispose S | Yes | No | 0.2942 | 4,324,008 | 1.27 mm | 0 |
20 Oct 23 | Theuer Charles | Common Stock | Grant | Acquire A | No | No | 0 | 3,500 | 0.00 | 406,417 |
27 Apr 23 | Theuer Charles | Common Stock | Buy | Acquire P | No | No | 0.75 | 47,000 | 35.25 k | 399,417 |
26 Apr 23 | Theuer Charles | Common Stock | Buy | Acquire P | No | No | 0.66 | 3,999 | 2.64 k | 352,417 |
20 Apr 23 | Scott B. Brown | Common Stock | Grant | Acquire A | No | No | 0 | 3,500 | 0.00 | 25,128 |
20 Apr 23 | Theuer Charles | Common Stock | Grant | Acquire A | No | No | 0 | 3,500 | 0.00 | 402,917 |
19 Apr 23 | Twiford J Rainer | Director Stock Option Common Stock | Grant | Acquire A | No | No | 1.82 | 18,000 | 32.76 k | 18,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Apr 24
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
15 Apr 24
Press releases
TRACON Pharmaceuticals Announces Reverse Stock Split
8 Apr 24
Thinking about buying stock in BigBear.ai, MicroCloud Hologram, TRACON Pharmaceuticals, Spruce Biosciences, or Recursion Pharmaceuticals?
14 Mar 24
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
5 Mar 24
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
28 Feb 24